Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Bessemer Group Inc.

Bessemer Group Inc. lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 52.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 79,140 shares of the biotechnology company’s stock after acquiring an additional 27,345 shares during the quarter. Bessemer Group Inc.’s holdings in Arrowhead Pharmaceuticals were worth $4,962,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $25,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $32,000. WPG Advisers LLC grew its position in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 431 shares during the period. Hantz Financial Services Inc. grew its position in shares of Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 471 shares during the period. Finally, Elyxium Wealth LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $54,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $71.65 on Tuesday. The firm has a market cap of $10.09 billion, a P/E ratio of -33.33 and a beta of 1.26. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $87.83. The stock’s fifty day moving average price is $77.50 and its 200-day moving average price is $69.51.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. The company had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.75 earnings per share. On average, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ARWR shares. Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price target for the company. Chardan Capital reissued a “buy” rating and issued a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, June 30th. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Sanford C. Bernstein upped their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings lowered Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $88.75.

Insider Activity

In related news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the transaction, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider owned 226,958 shares of the company’s stock, valued at approximately $17,021,850. This represents a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 26,065 shares of company stock worth $1,912,662. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.